publication . Article . 2019

Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.

Gini F. Fleming; B.D. Green; Kyle Hernandez; Kathleen R. Bowie; Caroline R. Kim; Mayra A. Betancourt-Ponce; Eva Tonsing-Carter; Ryan V. Harkless; Sarat Chandarlapaty; Diana C. West-Szymanski; ...
Open Access English
  • Published: 01 Jul 2019 Journal: Breast Cancer Research (issn: 1465-542X, Copyright policy)
  • Publisher: BMC
Abstract
Background Non-ER nuclear receptor activity can alter estrogen receptor (ER) chromatin association and resultant ER-mediated transcription. Consistent with GR modulation of ER activity, high tumor glucocorticoid receptor (GR) expression correlates with improved relapse-free survival in ER+ breast cancer (BC) patients. Methods In vitro cell proliferation assays were used to assess ER-mediated BC cell proliferation following GR modulation. ER chromatin association following ER/GR co-liganding was measured using global ChIP sequencing and directed ChIP analysis of proliferative gene enhancers. Results We found that GR liganding with either a pure agonist or a selec...
Subjects
free text keywords: Breast cancer, Estrogen receptor, Glucocorticoid receptor, Mutant activated estrogen receptor, Nuclear receptor crosstalk, Chromatin association, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cancer Research, Oncology, Research Article, Cyclin D1, Regulation of gene expression, Nuclear receptor, Chemistry, Gene expression, Chromatin, Enhancer, Cell biology, ChIP-sequencing
Funded by
NIH| Cancer Center Support Grant
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 3P30CA014599-36S1
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Investigate the role of TPD52-AMPK pathway in tumorigenesis and cancer therapy
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1R01CA196648-01A1
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Therapeutic approaches to ER mutant breast cancer
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1R01CA204999-01A1
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| MOUSE GENETICS
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P30CA008748-43
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Glucocorticoid receptor-mediated survival signaling in breast cancer
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01CA089208-08
  • Funding stream: NATIONAL CANCER INSTITUTE
52 references, page 1 of 4

Mohammed, Hisham, Russell, I. Alasdair, Stark, Rory, Rueda, Oscar M., Hickey, Theresa E., Tarulli, Gerard A., Serandour, Aurelien A., Birrell, Stephen N., Bruna, Alejandra, Saadi, Amel, Menon, Suraj, Hadfield, James, Pugh, Michelle, Raj, Ganesh V., Brown, Gordon D., D’Santos, Clive, Robinson, Jessica L. L., Silva, Grace, Launchbury, Rosalind, Perou, Charles M., Stingl, John, Caldas, Carlos, Tilley, Wayne D., Carroll, Jason S.. Progesterone receptor modulates ERα action in breast cancer. Nature. 2015; 523 (7560): 313-317 [OpenAIRE] [PubMed]

Singhal, H, Greene, ME, Tarulli, G, Zarnke, AL, Bourgo, RJ, Laine, M, Chang, YF, Ma, S, Dembo, AG, Raj, GV. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Sci Adv. 2016; 2 (6): e1501924 [OpenAIRE] [PubMed]

Yang, F, Ma, Q, Liu, Z, Li, W, Tan, Y, Jin, C, Ma, W, Hu, Y, Shen, J, Ohgi, KA. Glucocorticoid receptor: MegaTrans switching mediates the repression of an ERalpha-regulated transcriptional program. Mol Cell. 2017; 66 (3): 321-331 [OpenAIRE] [PubMed]

Cochrane, DR, Bernales, S, Jacobsen, BM, Cittelly, DM, Howe, EN, D'Amato, NC, Spoelstra, NS, Edgerton, SM, Jean, A, Guerrero, J. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014; 16 (1): R7 [OpenAIRE] [PubMed]

Lim, E, Tarulli, G, Portman, N, Hickey, TE, Tilley, WD, Palmieri, C. Pushing estrogen receptor around in breast cancer. Endocr Relat Cancer. 2016; 23 (12): T227-T241 [PubMed]

Bolt, MJ, Stossi, F, Newberg, JY, Orjalo, A, Johansson, HE, Mancini, MA. Coactivators enable glucocorticoid receptor recruitment to fine-tune estrogen receptor transcriptional responses. Nucleic Acids Res. 2013; 41 (7): 4036-4048 [OpenAIRE] [PubMed]

Karmakar, S, Jin, Y, Nagaich, AK. Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) alpha and activator protein 1 (AP1) in dexamethasone-mediated interference of ERalpha activity. J Biol Chem. 2013; 288 (33): 24020-24034 [OpenAIRE] [PubMed]

Miranda, TB, Voss, TC, Sung, MH, Baek, S, John, S, Hawkins, M, Grontved, L, Schiltz, RL, Hager, GL. Reprogramming the chromatin landscape: interplay of the estrogen and glucocorticoid receptors at the genomic level. Cancer Res. 2013; 73 (16): 5130-5139 [OpenAIRE] [PubMed]

West, DC, Pan, D, Tonsing-Carter, EY, Hernandez, KM, Pierce, CF, Styke, SC, Bowie, KR, Garcia, TI, Kocherginsky, M, Conzen, SD. GR and ER coactivation alters the expression of differentiation genes and associates with improved ER+ breast cancer outcome. Mol Cancer Res. 2016; 14 (8): 707-719 [OpenAIRE] [PubMed]

Tangen, IL, Veneris, JT, Halle, MK, Werner, HM, Trovik, J, Akslen, LA, Salvesen, HB, Conzen, SD, Fleming, GF, Krakstad, C. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecol Oncol. 2017; 147 (3): 672-677 [OpenAIRE] [PubMed]

Vahrenkamp, JM, Yang, CH, Rodriguez, AC, Almomen, A, Berrett, KC, Trujillo, AN, Guillen, KP, Welm, BE, Jarboe, EA, Janat-Amsbury, MM. Clinical and genomic crosstalk between glucocorticoid receptor and estrogen receptor alpha in endometrial cancer. Cell Rep. 2018; 22 (11): 2995-3005 [OpenAIRE] [PubMed]

Pan, D, Kocherginsky, M, Conzen, SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 2011; 71 (20): 6360-6370 [OpenAIRE] [PubMed]

Onitilo, AA, Engel, JM, Greenlee, RT, Mukesh, BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009; 7 (1–2): 4-13 [OpenAIRE] [PubMed]

Paakinaho, V, Presman, DM, Ball, DA, Johnson, TA, Schiltz, RL, Levitt, P, Mazza, D, Morisaki, T, Karpova, TS, Hager, GL. Single-molecule analysis of steroid receptor and cofactor action in living cells. Nat Commun. 2017; 8: 15896 [OpenAIRE] [PubMed]

Meijsing, SH, Pufall, MA, So, AY, Bates, DL, Chen, L, Yamamoto, KR. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science. 2009; 324 (5925): 407-410 [OpenAIRE] [PubMed]

52 references, page 1 of 4
Abstract
Background Non-ER nuclear receptor activity can alter estrogen receptor (ER) chromatin association and resultant ER-mediated transcription. Consistent with GR modulation of ER activity, high tumor glucocorticoid receptor (GR) expression correlates with improved relapse-free survival in ER+ breast cancer (BC) patients. Methods In vitro cell proliferation assays were used to assess ER-mediated BC cell proliferation following GR modulation. ER chromatin association following ER/GR co-liganding was measured using global ChIP sequencing and directed ChIP analysis of proliferative gene enhancers. Results We found that GR liganding with either a pure agonist or a selec...
Subjects
free text keywords: Breast cancer, Estrogen receptor, Glucocorticoid receptor, Mutant activated estrogen receptor, Nuclear receptor crosstalk, Chromatin association, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cancer Research, Oncology, Research Article, Cyclin D1, Regulation of gene expression, Nuclear receptor, Chemistry, Gene expression, Chromatin, Enhancer, Cell biology, ChIP-sequencing
Funded by
NIH| Cancer Center Support Grant
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 3P30CA014599-36S1
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Investigate the role of TPD52-AMPK pathway in tumorigenesis and cancer therapy
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1R01CA196648-01A1
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Therapeutic approaches to ER mutant breast cancer
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1R01CA204999-01A1
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| MOUSE GENETICS
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P30CA008748-43
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Glucocorticoid receptor-mediated survival signaling in breast cancer
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01CA089208-08
  • Funding stream: NATIONAL CANCER INSTITUTE
52 references, page 1 of 4

Mohammed, Hisham, Russell, I. Alasdair, Stark, Rory, Rueda, Oscar M., Hickey, Theresa E., Tarulli, Gerard A., Serandour, Aurelien A., Birrell, Stephen N., Bruna, Alejandra, Saadi, Amel, Menon, Suraj, Hadfield, James, Pugh, Michelle, Raj, Ganesh V., Brown, Gordon D., D’Santos, Clive, Robinson, Jessica L. L., Silva, Grace, Launchbury, Rosalind, Perou, Charles M., Stingl, John, Caldas, Carlos, Tilley, Wayne D., Carroll, Jason S.. Progesterone receptor modulates ERα action in breast cancer. Nature. 2015; 523 (7560): 313-317 [OpenAIRE] [PubMed]

Singhal, H, Greene, ME, Tarulli, G, Zarnke, AL, Bourgo, RJ, Laine, M, Chang, YF, Ma, S, Dembo, AG, Raj, GV. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Sci Adv. 2016; 2 (6): e1501924 [OpenAIRE] [PubMed]

Yang, F, Ma, Q, Liu, Z, Li, W, Tan, Y, Jin, C, Ma, W, Hu, Y, Shen, J, Ohgi, KA. Glucocorticoid receptor: MegaTrans switching mediates the repression of an ERalpha-regulated transcriptional program. Mol Cell. 2017; 66 (3): 321-331 [OpenAIRE] [PubMed]

Cochrane, DR, Bernales, S, Jacobsen, BM, Cittelly, DM, Howe, EN, D'Amato, NC, Spoelstra, NS, Edgerton, SM, Jean, A, Guerrero, J. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014; 16 (1): R7 [OpenAIRE] [PubMed]

Lim, E, Tarulli, G, Portman, N, Hickey, TE, Tilley, WD, Palmieri, C. Pushing estrogen receptor around in breast cancer. Endocr Relat Cancer. 2016; 23 (12): T227-T241 [PubMed]

Bolt, MJ, Stossi, F, Newberg, JY, Orjalo, A, Johansson, HE, Mancini, MA. Coactivators enable glucocorticoid receptor recruitment to fine-tune estrogen receptor transcriptional responses. Nucleic Acids Res. 2013; 41 (7): 4036-4048 [OpenAIRE] [PubMed]

Karmakar, S, Jin, Y, Nagaich, AK. Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) alpha and activator protein 1 (AP1) in dexamethasone-mediated interference of ERalpha activity. J Biol Chem. 2013; 288 (33): 24020-24034 [OpenAIRE] [PubMed]

Miranda, TB, Voss, TC, Sung, MH, Baek, S, John, S, Hawkins, M, Grontved, L, Schiltz, RL, Hager, GL. Reprogramming the chromatin landscape: interplay of the estrogen and glucocorticoid receptors at the genomic level. Cancer Res. 2013; 73 (16): 5130-5139 [OpenAIRE] [PubMed]

West, DC, Pan, D, Tonsing-Carter, EY, Hernandez, KM, Pierce, CF, Styke, SC, Bowie, KR, Garcia, TI, Kocherginsky, M, Conzen, SD. GR and ER coactivation alters the expression of differentiation genes and associates with improved ER+ breast cancer outcome. Mol Cancer Res. 2016; 14 (8): 707-719 [OpenAIRE] [PubMed]

Tangen, IL, Veneris, JT, Halle, MK, Werner, HM, Trovik, J, Akslen, LA, Salvesen, HB, Conzen, SD, Fleming, GF, Krakstad, C. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecol Oncol. 2017; 147 (3): 672-677 [OpenAIRE] [PubMed]

Vahrenkamp, JM, Yang, CH, Rodriguez, AC, Almomen, A, Berrett, KC, Trujillo, AN, Guillen, KP, Welm, BE, Jarboe, EA, Janat-Amsbury, MM. Clinical and genomic crosstalk between glucocorticoid receptor and estrogen receptor alpha in endometrial cancer. Cell Rep. 2018; 22 (11): 2995-3005 [OpenAIRE] [PubMed]

Pan, D, Kocherginsky, M, Conzen, SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 2011; 71 (20): 6360-6370 [OpenAIRE] [PubMed]

Onitilo, AA, Engel, JM, Greenlee, RT, Mukesh, BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009; 7 (1–2): 4-13 [OpenAIRE] [PubMed]

Paakinaho, V, Presman, DM, Ball, DA, Johnson, TA, Schiltz, RL, Levitt, P, Mazza, D, Morisaki, T, Karpova, TS, Hager, GL. Single-molecule analysis of steroid receptor and cofactor action in living cells. Nat Commun. 2017; 8: 15896 [OpenAIRE] [PubMed]

Meijsing, SH, Pufall, MA, So, AY, Bates, DL, Chen, L, Yamamoto, KR. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science. 2009; 324 (5925): 407-410 [OpenAIRE] [PubMed]

52 references, page 1 of 4
Any information missing or wrong?Report an Issue